EP2374887A3 - Method for isolation of soluble polypeptides - Google Patents

Method for isolation of soluble polypeptides Download PDF

Info

Publication number
EP2374887A3
EP2374887A3 EP10190201A EP10190201A EP2374887A3 EP 2374887 A3 EP2374887 A3 EP 2374887A3 EP 10190201 A EP10190201 A EP 10190201A EP 10190201 A EP10190201 A EP 10190201A EP 2374887 A3 EP2374887 A3 EP 2374887A3
Authority
EP
European Patent Office
Prior art keywords
identified
polypeptides
phage
human
biophysical properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10190201A
Other languages
German (de)
French (fr)
Other versions
EP2374887A2 (en
Inventor
Jamshid Tanha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of EP2374887A2 publication Critical patent/EP2374887A2/en
Publication of EP2374887A3 publication Critical patent/EP2374887A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)

Abstract

Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs or VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified many be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.
EP10190201A 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides Withdrawn EP2374887A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66495405P 2005-03-25 2005-03-25
EP06721715A EP1869182B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP06721715.8 Division 2006-03-24

Publications (2)

Publication Number Publication Date
EP2374887A2 EP2374887A2 (en) 2011-10-12
EP2374887A3 true EP2374887A3 (en) 2012-07-18

Family

ID=37023360

Family Applications (46)

Application Number Title Priority Date Filing Date
EP10190147A Withdrawn EP2368995A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190153A Withdrawn EP2322622A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190100A Withdrawn EP2368992A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190222A Withdrawn EP2316948A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190158A Withdrawn EP2339001A2 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190244A Withdrawn EP2368997A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190225.2A Active EP2377935B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190145A Withdrawn EP2368994A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190187.4A Not-in-force EP2322624B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP06721715A Not-in-force EP1869182B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190242.7A Active EP2360256B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190155.1A Not-in-force EP2360255B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190173A Withdrawn EP2371960A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190149A Withdrawn EP2363485A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190249A Withdrawn EP2338998A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190169A Withdrawn EP2336326A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190247A Withdrawn EP2330196A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190237A Withdrawn EP2336328A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190180A Withdrawn EP2345723A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190205A Withdrawn EP2338997A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190201A Withdrawn EP2374887A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190246A Withdrawn EP2333067A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190089A Withdrawn EP2333068A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190102A Withdrawn EP2368993A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190082A Withdrawn EP2316946A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190248.4A Not-in-force EP2333066B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190165A Withdrawn EP2336325A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190215A Withdrawn EP2330195A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190091A Withdrawn EP2338999A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190093.4A Not-in-force EP2368991B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190150A Withdrawn EP2336324A2 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190194A Withdrawn EP2322621A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190210A Withdrawn EP2351842A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190176A Withdrawn EP2351841A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190104A Withdrawn EP2336323A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190240A Withdrawn EP2377936A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190236A Withdrawn EP2336327A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190233A Withdrawn EP2368996A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190177A Withdrawn EP2339000A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190143.7A Active EP2374886B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190232A Withdrawn EP2316945A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190162A Withdrawn EP2322623A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190086A Withdrawn EP2368990A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190235A Withdrawn EP2371961A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190206A Withdrawn EP2386638A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190160A Withdrawn EP2316947A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides

Family Applications Before (20)

Application Number Title Priority Date Filing Date
EP10190147A Withdrawn EP2368995A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190153A Withdrawn EP2322622A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190100A Withdrawn EP2368992A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190222A Withdrawn EP2316948A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190158A Withdrawn EP2339001A2 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190244A Withdrawn EP2368997A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190225.2A Active EP2377935B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190145A Withdrawn EP2368994A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190187.4A Not-in-force EP2322624B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP06721715A Not-in-force EP1869182B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190242.7A Active EP2360256B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190155.1A Not-in-force EP2360255B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190173A Withdrawn EP2371960A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190149A Withdrawn EP2363485A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190249A Withdrawn EP2338998A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190169A Withdrawn EP2336326A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190247A Withdrawn EP2330196A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190237A Withdrawn EP2336328A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190180A Withdrawn EP2345723A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190205A Withdrawn EP2338997A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides

Family Applications After (25)

Application Number Title Priority Date Filing Date
EP10190246A Withdrawn EP2333067A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190089A Withdrawn EP2333068A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190102A Withdrawn EP2368993A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190082A Withdrawn EP2316946A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190248.4A Not-in-force EP2333066B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190165A Withdrawn EP2336325A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190215A Withdrawn EP2330195A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190091A Withdrawn EP2338999A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190093.4A Not-in-force EP2368991B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190150A Withdrawn EP2336324A2 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190194A Withdrawn EP2322621A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190210A Withdrawn EP2351842A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190176A Withdrawn EP2351841A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190104A Withdrawn EP2336323A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190240A Withdrawn EP2377936A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190236A Withdrawn EP2336327A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190233A Withdrawn EP2368996A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190177A Withdrawn EP2339000A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190143.7A Active EP2374886B1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190232A Withdrawn EP2316945A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190162A Withdrawn EP2322623A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190086A Withdrawn EP2368990A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190235A Withdrawn EP2371961A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190206A Withdrawn EP2386638A3 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides
EP10190160A Withdrawn EP2316947A1 (en) 2005-03-25 2006-03-24 Method for isolation of soluble polypeptides

Country Status (10)

Country Link
US (5) US8293233B2 (en)
EP (46) EP2368995A3 (en)
JP (7) JP5171611B2 (en)
AT (1) ATE531800T1 (en)
AU (1) AU2006227536B9 (en)
CA (8) CA2602028C (en)
ES (8) ES2375826T3 (en)
PL (1) PL2360255T3 (en)
PT (1) PT2360255E (en)
WO (1) WO2006099747A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261241A1 (en) 2001-04-16 2010-12-15 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
BRPI0516974A (en) 2004-10-21 2008-09-30 Wyeth Corp immunogenic composition comprising a polypeptide; a method for inducing an immune response against staphylococcus epidermidis; a method for inducing an immune response against staphylococcus aureus; a method for the detection and / or identification of staphylococcus epidermidis; a method for the detection and / or identification of antibodies to staphylococcus epidermidis
EP2368995A3 (en) * 2005-03-25 2012-01-18 National Research Council of Canada Method for isolation of soluble polypeptides
SI2158315T1 (en) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Methods of modifying antibodies, and modified antibodies with improved functional properties
US9181327B2 (en) * 2008-01-07 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-HIV domain antibodies and method of making and using same
US20110269148A1 (en) * 2008-11-26 2011-11-03 National Cheng Chung University Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies
US9771416B2 (en) 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
AU2012211011A1 (en) 2011-01-28 2013-08-15 National Research Council Of Canada Engineering of immunoglobulin domains
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
BR112015026716A2 (en) 2013-04-23 2017-09-05 The Univ Court Of The Univ Of Aberdeen ICOSL-SPECIFIC ANTIGEN-BINDING MOLECULE; FUSION PROTEIN; NUCLEIC ACID ENCODING AN ICOSL-SPECIFIC ANTIGEN-BINDING MOLECULE; NUCLEIC ACID CONSTRUCT; HOST CELL; PROCESS FOR PRODUCING AN ICOSL-SPECIFIC ANTIGEN-BINDING MOLECULE; PHARMACEUTICAL COMPOSITION OF AN ICOSL-SPECIFIC ANTIGEN-BINDING MOLECULE; USE OF AN ICOSL-SPECIFIC ANTIGEN-BINDING MOLECULE; METHOD OF TREATMENT OF AN ILLNESS IN A PATIENT IN NEED OF TREATMENT; METHOD OF ASSAYING A TARGET ANALYTE IN A SAMPLE; METHOD OF IMAGE FORMATION OF A DISEASE SITE IN AN INDIVIDUAL; AND METHOD OF DIAGNOSIS OF A DISEASE OR MEDICAL CONDITION IN AN INDIVIDUAL
WO2016097315A2 (en) * 2014-12-19 2016-06-23 Medimmune Limited Blood brain barrier transport molecules and uses thereof
BR112017015582A2 (en) 2015-01-23 2018-03-13 Helix Biopharma Corp antibody-urease conjugates for therapeutic purposes
HRP20220436T1 (en) * 2015-11-03 2022-05-27 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN112135622A (en) 2018-03-06 2020-12-25 普莱西根股份有限公司 Hepatitis B vaccine and uses thereof
EP3762022A4 (en) * 2018-03-06 2022-06-15 Precigen, Inc. Human papillomavirus vaccines and uses of the same
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
EP4077376A2 (en) 2019-12-19 2022-10-26 Quidel Corporation Monoclonal antibody fusions
AR124914A1 (en) * 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp NEW ANTI-PAD4 ANTIBODY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001581A1 (en) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Method of dna shuffling with polynucleotides produced by blockingor interrupting a synthesis or amplification process
WO2002051870A2 (en) * 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
WO2004005890A2 (en) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof
EP1479694A2 (en) * 1999-12-28 2004-11-24 Esbatech AG Intrabodies ScFv with defined framework that is stable in a reducing environment

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0542810A1 (en) * 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
DE69233204T2 (en) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP1171468B1 (en) * 1999-04-09 2008-07-02 Universität Zürich Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
AU2001252970A1 (en) * 2000-03-27 2001-10-08 The Regents Of The University Of California Ligands directed to the non-secretory component, non-stalk region of pIgR and methods of use thereof
AU2000239309A1 (en) 2000-03-29 2001-10-08 Dgi Biotechnologies Llc Insulin and igf-1 receptor agonists and antagonists
DE60035337T2 (en) 2000-05-12 2008-02-28 Gpc Biotech Ag Human peptides / proteins that cause or cause the killing of cells, including lymphoid tumor cells
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
JP3375941B2 (en) 2000-11-24 2003-02-10 科学技術振興事業団 Highly efficient antibody screening method
WO2002059340A1 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Immunopolypeptides to hepatitis c virus
DE10123041A1 (en) * 2001-05-11 2002-11-28 Tobias Heintges New single-chain human antibody fragment, useful for treating or diagnosing hepatitis C virus infection, has affinity for an essential viral protein
EP1425694A2 (en) * 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
EP1429143A4 (en) * 2001-08-22 2006-04-12 Inst Antibodies Co Ltd Method of selecting binding molecule
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
WO2003059937A2 (en) 2002-01-14 2003-07-24 Washington University Synthetic ion channels
WO2003070752A2 (en) * 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
CA2867542C (en) 2002-05-22 2020-04-14 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2003102136A2 (en) * 2002-05-30 2003-12-11 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
AU2003239197A1 (en) * 2002-06-07 2003-12-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Novel stable anti-cd22 antibodies
CN1678634A (en) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variable antigen combination area and its opposite constituent
CA2506128A1 (en) * 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
RU2005131852A (en) * 2003-03-14 2006-04-20 Уайт (Us) ANTIBODIES AGAINST THE HUMAN RECEPTOR IL-21 AND THEIR APPLICATION
EP1633316A4 (en) * 2003-05-06 2008-04-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
AR045614A1 (en) 2003-09-10 2005-11-02 Hoffmann La Roche ANTIBODIES AGAINST THE RECEIVER OF INTERLEUQUINA- 1 AND USES OF THE SAME
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
MXPA06010887A (en) * 2004-03-23 2007-03-08 Amgen Inc Monoclonal antibodies.
DE602005020799D1 (en) * 2004-08-05 2010-06-02 Genentech Inc HUMANIZED ANTI-CMET ANTAGONISTS
AU2005272848A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
EP2368995A3 (en) 2005-03-25 2012-01-18 National Research Council of Canada Method for isolation of soluble polypeptides
US20110269148A1 (en) * 2008-11-26 2011-11-03 National Cheng Chung University Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies
AU2012211011A1 (en) * 2011-01-28 2013-08-15 National Research Council Of Canada Engineering of immunoglobulin domains
WO2014043509A2 (en) * 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001581A1 (en) * 1996-07-09 1998-01-15 Recombinant Biocatalysis, Inc. Method of dna shuffling with polynucleotides produced by blockingor interrupting a synthesis or amplification process
EP1479694A2 (en) * 1999-12-28 2004-11-24 Esbatech AG Intrabodies ScFv with defined framework that is stable in a reducing environment
WO2002051870A2 (en) * 2000-12-22 2002-07-04 GRAD, Carole Legal Representative of KAPLAN, Howard Phage display libraries of human vh fragments
WO2004005890A2 (en) * 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUDSON P J ET AL: "High avidity scFv multimers; diabodies and triabodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 177 - 189, XP004186084, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(99)00157-X *
PECH M ET AL: "IMMUNOGLOBULIN GENES OF DIFFERENT SUBGROUPS ARE INTERDIGITATED WITHIN THE VK LOCUS", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 24, 1 January 1984 (1984-01-01), pages 9229 - 9236, XP008026512, ISSN: 0305-1048 *
TO R ET AL: "Isolation of Monomeric Human VHS by a Phage Selection", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 280, no. 50, 16 December 2005 (2005-12-16), pages 41395 - 41403, XP009100333, ISSN: 0021-9258, DOI: 10.1074/JBC.M509900200 *
WANG XIANG-BIN ET AL: "A new approach for rapidly reshaping single-chain antibody in vitro by combining DNA shuffling with ribosome display", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 136, no. 1, July 2004 (2004-07-01), pages 19 - 28, XP002626886, ISSN: 0021-924X *
WOERN A ET AL: "Stability engineering of antibody single-chain Fv fragments", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 305, no. 5, 1 January 2001 (2001-01-01), pages 989 - 1010, XP002249286, ISSN: 0022-2836, DOI: 10.1006/JMBI.2000.4265 *

Also Published As

Publication number Publication date
EP2322624B1 (en) 2015-09-23
JP5901679B2 (en) 2016-04-13
ES2536995T3 (en) 2015-06-01
PT2360255E (en) 2015-04-08
EP2368994A2 (en) 2011-09-28
EP2368995A3 (en) 2012-01-18
EP2377935B1 (en) 2015-07-15
EP2322623A3 (en) 2011-10-19
EP2336323A2 (en) 2011-06-22
ES2546788T3 (en) 2015-09-28
ES2565782T3 (en) 2016-04-06
JP6628822B2 (en) 2020-01-15
AU2006227536B9 (en) 2011-08-18
EP2322624A3 (en) 2012-03-14
ES2531537T3 (en) 2015-03-17
EP2386638A3 (en) 2012-08-15
US8293233B2 (en) 2012-10-23
JP5171611B2 (en) 2013-03-27
CA2873899A1 (en) 2006-09-28
JP2018110583A (en) 2018-07-19
JP6374851B2 (en) 2018-08-15
US20130142780A1 (en) 2013-06-06
EP2368997A2 (en) 2011-09-28
CA2873906C (en) 2020-11-24
EP2360255A1 (en) 2011-08-24
US20090220485A1 (en) 2009-09-03
ATE531800T1 (en) 2011-11-15
EP2336328A1 (en) 2011-06-22
EP2316945A1 (en) 2011-05-04
EP2351841A1 (en) 2011-08-03
EP1869182A4 (en) 2008-08-13
EP2336326A3 (en) 2012-02-15
CA2868867A1 (en) 2006-09-28
JP2008536490A (en) 2008-09-11
CA2873899C (en) 2020-11-10
EP2368991B1 (en) 2016-02-17
ES2375826T3 (en) 2012-03-06
EP2371961A1 (en) 2011-10-05
EP2377936A3 (en) 2012-06-13
EP2316948A1 (en) 2011-05-04
CA2868774A1 (en) 2006-09-28
AU2006227536B2 (en) 2011-08-11
JP6878508B2 (en) 2021-05-26
EP2322621A2 (en) 2011-05-18
EP2333067A1 (en) 2011-06-15
EP2368993A3 (en) 2012-06-13
US11091536B2 (en) 2021-08-17
US10150807B2 (en) 2018-12-11
CA2602028A1 (en) 2006-09-28
CA2868865A1 (en) 2006-09-28
EP2374886A3 (en) 2011-11-23
US20160052995A1 (en) 2016-02-25
EP2333066B1 (en) 2015-02-18
EP2338999A3 (en) 2012-05-23
EP2330195A2 (en) 2011-06-08
EP2316947A1 (en) 2011-05-04
EP2368992A2 (en) 2011-09-28
EP2368996A3 (en) 2011-12-14
CA2873939C (en) 2020-11-10
EP2374886A2 (en) 2011-10-12
EP2360256B1 (en) 2014-12-31
EP2368995A2 (en) 2011-09-28
EP1869182B1 (en) 2011-11-02
EP2371960A2 (en) 2011-10-05
JP2012070748A (en) 2012-04-12
EP2386638A2 (en) 2011-11-16
EP2360256A1 (en) 2011-08-24
ES2550836T3 (en) 2015-11-12
EP2368994A3 (en) 2012-04-18
EP2374886B1 (en) 2015-11-11
EP2322621A3 (en) 2012-09-12
EP2377935A1 (en) 2011-10-19
EP2339000A1 (en) 2011-06-29
JP2014144010A (en) 2014-08-14
EP2368990A1 (en) 2011-09-28
ES2558338T3 (en) 2016-02-03
CA2602028C (en) 2015-01-13
EP2351842A1 (en) 2011-08-03
US20190092840A1 (en) 2019-03-28
EP2368991A2 (en) 2011-09-28
EP2363485A1 (en) 2011-09-07
EP2336327A1 (en) 2011-06-22
EP2360255B1 (en) 2015-01-28
EP2336323A3 (en) 2012-05-23
EP2322622A3 (en) 2012-03-07
EP2322623A2 (en) 2011-05-18
EP2330195A3 (en) 2012-05-23
JP5731956B2 (en) 2015-06-10
US11993643B2 (en) 2024-05-28
EP2322622A2 (en) 2011-05-18
EP2338998A1 (en) 2011-06-29
PL2360255T3 (en) 2015-05-29
EP2368991A3 (en) 2012-07-25
ES2534305T3 (en) 2015-04-21
EP2371960A3 (en) 2012-01-11
CA2873906A1 (en) 2006-09-28
JP2016073284A (en) 2016-05-12
EP2333066A1 (en) 2011-06-15
EP2336326A2 (en) 2011-06-22
CA2873939A1 (en) 2006-09-28
EP2338997A1 (en) 2011-06-29
EP2336324A2 (en) 2011-06-22
EP2338999A2 (en) 2011-06-29
EP2330196A2 (en) 2011-06-08
EP2368993A2 (en) 2011-09-28
AU2006227536A1 (en) 2006-09-28
US20220017603A1 (en) 2022-01-20
JP2019187439A (en) 2019-10-31
EP2316946A1 (en) 2011-05-04
EP2339001A2 (en) 2011-06-29
EP2368992A3 (en) 2012-03-14
WO2006099747A1 (en) 2006-09-28
EP2368997A3 (en) 2012-02-22
EP1869182A1 (en) 2007-12-26
EP2330196A3 (en) 2012-04-18
EP2374887A2 (en) 2011-10-12
EP2345723A1 (en) 2011-07-20
EP2336325A1 (en) 2011-06-22
EP2368996A2 (en) 2011-09-28
EP2333068A1 (en) 2011-06-15
EP2322624A2 (en) 2011-05-18
CA2868781A1 (en) 2006-09-28
EP2377936A2 (en) 2011-10-19
JP2016103998A (en) 2016-06-09

Similar Documents

Publication Publication Date Title
EP2386638A3 (en) Method for isolation of soluble polypeptides
EP2361926A3 (en) Yersinia SSP. polypeptides and methods of use
EP2606933A3 (en) Combination of an IAP-inhibitor and a taxane
WO2007084264A3 (en) Methods for myocardial imaging
EP2062917A3 (en) Antibodies to erythropoietin receptor and uses thereof
EP2363460A3 (en) Acid fungal proteases
EP2386539A3 (en) Modified lysine-mimetic compounds
WO2004093645A3 (en) Tn5 transposase mutants and the use thereof
EP3196213A3 (en) Antibodies directed to her-3 and uses thereof
EP2402321A3 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
EP2441847A3 (en) Screening methods using syk in combination with tau protein
EP2789626A3 (en) Peptides and compositions for prevention of cell adhesion and methods of using same
DE502005000428D1 (en) Process for the preparation of 1,2-diaminocyclohexane-platinum (II) complexes
WO2007023191A3 (en) Polypeptide marker for the diagnosis of bladder cancer
EP2322209A3 (en) Tumor specific oligosaccharide epitopes and use thereof
WO2007044844A3 (en) Tagging and retrieval of dna from casualties
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
WO2007068913A3 (en) SRCR-B Domain Containing Proteins
WO2006000464A3 (en) Method for discovering pain-relevant substances using pain-relevant proteins
WO2007108903A3 (en) Campylobacter vaccines and methods of use
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2007020405A3 (en) Integrin i-domain binding peptides
Luczynski Aminoestry kwasow tluszczowych jako substancje lizosomotropowe.
WO2006008266A3 (en) Factor xi-binding proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1869182

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/13 20060101AFI20120613BHEP

Ipc: C07K 16/00 20060101ALI20120613BHEP

Ipc: G01N 33/68 20060101ALI20120613BHEP

Ipc: C07K 16/12 20060101ALI20120613BHEP

Ipc: C12N 15/10 20060101ALI20120613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130119